Prelude Therapeutics Incorporated

NasdaqGS:PRLD Stock Report

Market Cap: US$52.8m

Prelude Therapeutics Valuation

Is PRLD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PRLD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PRLD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PRLD's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for PRLD?

Key metric: As PRLD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PRLD. This is calculated by dividing PRLD's market cap by their current revenue.
What is PRLD's PS Ratio?
PS Ratio17.6x
SalesUS$3.00m
Market CapUS$52.84m

Price to Sales Ratio vs Peers

How does PRLD's PS Ratio compare to its peers?

The above table shows the PS ratio for PRLD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average17.8x
CNTB Connect Biopharma Holdings
2.4x14.3%US$53.9m
XFOR X4 Pharmaceuticals
51.7x64.3%US$62.8m
XLO Xilio Therapeutics
9x1.0%US$44.8m
IVVD Invivyd
7.9x56.9%US$91.8m
PRLD Prelude Therapeutics
17.6x73.3%US$52.8m

Price-To-Sales vs Peers: PRLD is good value based on its Price-To-Sales Ratio (17.6x) compared to the peer average (17.8x).


Price to Sales Ratio vs Industry

How does PRLD's PS Ratio compare vs other companies in the US Biotechs Industry?

131 CompaniesPrice / SalesEstimated GrowthMarket Cap
GILD Gilead Sciences
3.9x2.4%US$109.25b
BIIB Biogen
2.4x1.3%US$22.65b
MRNA Moderna
2.8x7.2%US$14.35b
INCY Incyte
3.4x8.9%US$13.59b
PRLD 17.6xIndustry Avg. 10.1xNo. of Companies131PS01632486480+
131 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: PRLD is expensive based on its Price-To-Sales Ratio (17.6x) compared to the US Biotechs industry average (10.3x).


Price to Sales Ratio vs Fair Ratio

What is PRLD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PRLD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio17.6x
Fair PS Ratio30.4x

Price-To-Sales vs Fair Ratio: PRLD is good value based on its Price-To-Sales Ratio (17.6x) compared to the estimated Fair Price-To-Sales Ratio (30.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PRLD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.96
US$5.40
+461.5%
55.7%US$10.00US$1.00n/a5
Nov ’25US$1.24
US$5.40
+335.5%
55.7%US$10.00US$1.00n/a5
Oct ’25US$2.03
US$5.80
+185.7%
42.8%US$10.00US$3.00n/a5
Sep ’25US$5.20
US$5.80
+11.5%
42.8%US$10.00US$3.00n/a5
Aug ’25US$5.65
US$4.75
-15.9%
31.1%US$7.00US$3.00n/a4
Jul ’25US$3.77
US$4.75
+26.0%
31.1%US$7.00US$3.00n/a4
Jun ’25US$3.85
US$4.75
+23.4%
31.1%US$7.00US$3.00n/a4
May ’25US$3.73
US$4.75
+27.3%
31.1%US$7.00US$3.00n/a4
Apr ’25US$4.69
US$4.75
+1.3%
31.1%US$7.00US$3.00n/a4
Mar ’25US$4.59
US$4.00
-12.9%
20.4%US$5.00US$3.00n/a3
Feb ’25US$3.27
US$4.50
+37.6%
11.1%US$5.00US$4.00n/a2
Jan ’25US$4.27
US$4.00
-6.3%
20.4%US$5.00US$3.00n/a3
Dec ’24US$3.23
US$6.00
+86.0%
49.1%US$10.00US$3.00n/a3
Nov ’24US$1.86
US$7.75
+316.7%
29.4%US$10.00US$5.00US$1.244
Oct ’24US$3.09
US$10.50
+239.8%
40.7%US$17.00US$5.00US$2.034
Sep ’24US$3.66
US$9.40
+156.8%
46.9%US$17.00US$5.00US$5.205
Aug ’24US$3.69
US$10.00
+171.0%
38.5%US$17.00US$6.00US$5.655
Jul ’24US$4.50
US$10.00
+122.2%
38.5%US$17.00US$6.00US$3.775
Jun ’24US$5.56
US$10.00
+79.9%
38.5%US$17.00US$6.00US$3.855
May ’24US$6.16
US$10.00
+62.3%
38.5%US$17.00US$6.00US$3.735
Apr ’24US$5.70
US$10.00
+75.4%
38.5%US$17.00US$6.00US$4.695
Mar ’24US$5.93
US$9.60
+61.9%
32.7%US$15.00US$6.00US$4.595
Feb ’24US$6.59
US$9.60
+45.7%
32.7%US$15.00US$6.00US$3.275
Jan ’24US$6.04
US$9.60
+58.9%
32.7%US$15.00US$6.00US$4.275
Dec ’23US$6.61
US$9.60
+45.2%
32.7%US$15.00US$6.00US$3.235
Nov ’23US$6.65
US$10.20
+53.4%
31.2%US$16.00US$7.00US$1.865

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies